Summary & Overview
HCPCS J9055: Cetuximab Injection, 10 mg
HCPCS Level II code J9055 denotes the administration of cetuximab, 10 mg, a monoclonal antibody used in oncology infusion therapy. Nationally, accurate coding of biologic oncology drugs like cetuximab is important for clinical documentation, payer adjudication, and drug utilization monitoring because these agents are high-cost and commonly administered in outpatient infusion settings. Key payers included in this coverage analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.
Readers will find a concise national overview of what J9055 represents, how it is used in infusion services, and what to expect when billing for cetuximab by unit dose. The publication covers benchmark elements such as common payer coverage patterns and coding practice considerations, recent policy updates affecting biologic drug billing, and clinical context about service delivery in outpatient infusion centers and physician offices. Where available, benchmarks summarize typical utilization and reimbursement approaches; where input data is not available, the text notes its absence. This resource is intended to support coding, billing, and administrative teams in aligning documentation and claims submission for cetuximab infusions across major commercial payers and Medicare.
Billing Code Overview
HCPCS Level II code J9055 represents an injection of cetuximab, 10 mg. This code is used to report administration of the monoclonal antibody cetuximab in a quantified drug shipping or infusion context.
Service Type: injectable biologic therapy
Typical Site of Service: hospital outpatient infusion center or physician office infusion suite for intravenous administration.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 62-year-old patient with newly diagnosed, KRAS wild-type, EGFR-expressing metastatic colorectal carcinoma presents to the oncology infusion center for systemic therapy. The treatment plan includes intravenous monoclonal antibody therapy with J9055 (cetuximab) dosed per body surface area. Prior to infusion, the nurse verifies allergy history, obtains baseline vital signs, and confirms premedication orders (e.g., antihistamine, antipyretic). A pharmacist compounds the vialed dose using appropriate aseptic technique and documents lot number and expiration. During administration, the patient is monitored for infusion-related reactions; infusion rate adjustments or interruption may be required for hypersensitivity. Post-infusion, the patient is observed for delayed reactions and instructed on dermatologic adverse effects, including acneiform rash and skin care. Clinicians document indication, dose (mg), units billed (per 10 mg), route, and any modifier(s) to reflect circumstances such as split/shared services or drug wastage. Typical site of service is an outpatient hospital infusion center or physician office-based infusion suite. Service type: outpatient therapeutic infusion of a monoclonal antibody.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
JW | Drug discarded/not administered to any patient | Report when part of the dispensed vial is discarded and cannot be reassigned |